Rich Pharmaceuticals, Inc. announced the potential for using its drug RP-323 (TPA) in the treatment of Hodgkin's lymphoma. Hodgkin’s lymphoma is a cancer that is found most frequently in two different age groups: 15 – 35 and over 55.  It occurs in both sexes although it is more common in males. Cancer cells invade and destroy the architecture of the lymph nodes and infiltrate the liver, the spleen or other parts of the body.  In the U.S., more than 100,000 people suffer from Hodgkin's lymphoma.